173 related articles for article (PubMed ID: 29076134)
1. Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.
Qiu Y; Li Z; Pouzoulet F; Vishnu P; Copland JA; Knutson KL; Soussain C; Tun HW
Br J Haematol; 2018 Nov; 183(4):674-678. PubMed ID: 29076134
[No Abstract] [Full Text] [Related]
2. (3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ.
Cao L; Dai C; Qin R; Guo Y; Liu J
Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):599-606. PubMed ID: 31691624
[No Abstract] [Full Text] [Related]
3. Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL.
Takashima Y; Kawaguchi A; Sato R; Yoshida K; Hayano A; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Nakano M; Ogawa S; Tashiro K; Yamanaka R
Sci Rep; 2019 Jul; 9(1):10004. PubMed ID: 31292525
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
5. [Immune-checkpoint and hemopathies].
Burroni B; Broudin C; Damotte D; Laurent C
Ann Pathol; 2017 Feb; 37(1):101-110. PubMed ID: 28161001
[TBL] [Abstract][Full Text] [Related]
6. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
7. The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma.
Miyasato Y; Takashima Y; Takeya H; Yano H; Hayano A; Nakagawa T; Makino K; Takeya M; Yamanaka R; Komohara Y
J Clin Exp Hematop; 2018; 58(2):95-101. PubMed ID: 29998979
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.
Kumar S; Ghosh S; Sharma G; Wang Z; Kehry MR; Marino MH; Neben TY; Lu S; Luo S; Roberts S; Ramaswamy S; Danaee H; Jenkins D
MAbs; 2021; 13(1):1954136. PubMed ID: 34313545
[TBL] [Abstract][Full Text] [Related]
9. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S
Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628
[TBL] [Abstract][Full Text] [Related]
10. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
Song MK; Park BB; Uhm J
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884772
[TBL] [Abstract][Full Text] [Related]
11. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.
Deng R; Bumbaca D; Pastuskovas CV; Boswell CA; West D; Cowan KJ; Chiu H; McBride J; Johnson C; Xin Y; Koeppen H; Leabman M; Iyer S
MAbs; 2016; 8(3):593-603. PubMed ID: 26918260
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
Nayak L; Iwamoto FM; LaCasce A; Mukundan S; Roemer MGM; Chapuy B; Armand P; Rodig SJ; Shipp MA
Blood; 2017 Jun; 129(23):3071-3073. PubMed ID: 28356247
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death-1 inhibition in lymphoma.
Hawkes EA; Grigg A; Chong G
Lancet Oncol; 2015 May; 16(5):e234-45. PubMed ID: 25943068
[TBL] [Abstract][Full Text] [Related]
15. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.
Yaghoubi N; Soltani A; Ghazvini K; Hassanian SM; Hashemy SI
Biomed Pharmacother; 2019 Feb; 110():312-318. PubMed ID: 30522017
[TBL] [Abstract][Full Text] [Related]
16. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
17. [Current events in immunotherapy for upper aerodigestive tract cancer].
Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
[TBL] [Abstract][Full Text] [Related]
18. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
Cheah CY; Fowler NH; Neelapu SS
Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
[TBL] [Abstract][Full Text] [Related]
19. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.
Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y
Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246
[TBL] [Abstract][Full Text] [Related]
20. Selection of PD1/PD-L1 X-Aptamers.
Wang H; Lam CH; Li X; West DL; Yang X
Biochimie; 2018 Feb; 145():125-130. PubMed ID: 28912094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
